Stockscreener 앱 받기
29.54
2.29%
0.66
시간 외 거래:
29.50
-0.04
-0.14%
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics, Inc. Revenue Breakdown – NASDAQ:QNCX - TradingView
QNCX|Quince Therapeutics Inc|Price:17.740|Chg%:-0.540 - TradingKey
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by One-Time GainEarnings Forecast Report - dars.gov.et
QNCX Q1 2026 Earnings: Stunning EPS Surprise of 210.29% as Company Reports $57.6 Per Share - dars.gov.et
Quince Therapeutics Surges Over 11% as Biotech Momentum BuildsAdvance Decline Line - dars.gov.et
QNCX Q1 2026 Earnings: EPS Surges to $57.6, Crushing Estimates Amid Strong Stock ReactionEarnings Revision Report - dars.gov.et
Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug - Ad Hoc News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - The National Law Review
QNCX Should I Buy - Intellectia AI
What date does Quince Therapeutics, Inc.'s (QNCX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
$Quince Therapeutics (QNCX.US)$ fake news !!! - Moomoo
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
QNCX Q1 2026 Earnings: Massive EPS Surprise Amid Stock Decline Raises QuestionsDiluted EPS Report - dars.gov.et
Quince Therapeutics forms advisory board for LAM-001 drug - Investing.com
Quince Therapeutics forms advisory board for LAM-001 drug By Investing.com - Investing.com India
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board - GlobeNewswire
LifeSci Capital Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $100 - Moomoo
Quince Therapeutics Implements 1-for-20 Reverse Stock Split - The Globe and Mail
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to earnings forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to EBIT forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink initiates Quince Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating - Investing.com UK
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating By Investing.com - Investing.com South Africa
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
Stay encouraged and keep believing in yourself - Moomoo
1.19%
1.50%
자본화:
|
볼륨(24시간):